Rapid Dose Therapeutics Corp. (DOSE.CN)
CAD 0.23
(-4.17%)
CAD 0.23
(-4.17%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -3.02 Million CAD | 15.55% |
| 2022 | -2.91 Million CAD | 17.32% |
| 2021 | -7.58 Million CAD | -142.99% |
| 2020 | -987.22 Thousand CAD | 79.0% |
| 2019 | -7.37 Million CAD | -121.65% |
| 2018 | -11.24 Million CAD | -6128.18% |
| 2017 | -50.07 Thousand CAD | -6.33% |
| 2016 | -47.09 Thousand CAD | 8.98% |
| 2015 | -51.74 Thousand CAD | 49.29% |
| 2014 | -102.03 Thousand CAD | -164.3% |
| 2013 | -38.6 Thousand CAD | -251.53% |
| 2012 | 25.47 Thousand CAD | 137.62% |
| 2011 | -67.72 Thousand CAD | 15.3% |
| 2010 | -79.95 Thousand CAD | -1074.96% |
| 2009 | -6805.00 CAD | -101.39% |
| 2008 | -3379.00 CAD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -807.29 Thousand CAD | 7.37% |
| 2024 Q1 | -871.52 Thousand CAD | 43.48% |
| 2023 Q3 | -725.65 Thousand CAD | -74.35% |
| 2023 FY | - CAD | 15.55% |
| 2023 Q1 | -318.65 Thousand CAD | 63.71% |
| 2023 Q2 | -416.21 Thousand CAD | -30.62% |
| 2023 Q4 | -980.17 Thousand CAD | -35.07% |
| 2022 Q4 | -878.07 Thousand CAD | -109.24% |
| 2022 Q1 | -862.11 Thousand CAD | 70.09% |
| 2022 Q2 | -758.18 Thousand CAD | 12.06% |
| 2022 FY | - CAD | 17.32% |
| 2022 Q3 | -419.65 Thousand CAD | 44.65% |
| 2021 FY | - CAD | -142.99% |
| 2021 Q1 | 303.25 Thousand CAD | 150.43% |
| 2021 Q2 | -352.7 Thousand CAD | -216.31% |
| 2021 Q3 | -603.14 Thousand CAD | -71.01% |
| 2021 Q4 | -2.88 Million CAD | -377.88% |
| 2020 FY | - CAD | 79.0% |
| 2020 Q2 | -83.34 Thousand CAD | 68.63% |
| 2020 Q3 | -311.94 Thousand CAD | -274.3% |
| 2020 Q4 | -601.33 Thousand CAD | -92.77% |
| 2020 Q1 | -265.69 Thousand CAD | 56.63% |
| 2019 FY | - CAD | -121.65% |
| 2019 Q4 | -612.59 Thousand CAD | 74.66% |
| 2019 Q1 | -3.18 Million CAD | 66.83% |
| 2019 Q3 | -2.41 Million CAD | -346.68% |
| 2019 Q2 | -541.18 Thousand CAD | 83.02% |
| 2018 Q2 | -491.94 Thousand CAD | -69.89% |
| 2018 Q1 | -289.57 Thousand CAD | 76.33% |
| 2018 FY | - CAD | -6128.18% |
| 2018 Q3 | -936.52 Thousand CAD | -90.37% |
| 2018 Q4 | -9.6 Million CAD | -925.86% |
| 2017 Q2 | -26.76 Thousand CAD | -319.2% |
| 2017 Q1 | -6384.00 CAD | -61.87% |
| 2017 Q4 | -1.22 Million CAD | -6213.5% |
| 2017 Q3 | -19.37 Thousand CAD | 27.59% |
| 2017 FY | - CAD | -6.33% |
| 2016 Q2 | -16.47 Thousand CAD | -823.14% |
| 2016 FY | - CAD | 8.98% |
| 2016 Q3 | -12.98 Thousand CAD | 21.17% |
| 2016 Q4 | -3944.00 CAD | 69.64% |
| 2016 Q1 | -1785.00 CAD | 89.47% |
| 2015 Q2 | -14.57 Thousand CAD | -69.02% |
| 2015 Q4 | -16.94 Thousand CAD | -42.69% |
| 2015 FY | - CAD | 49.29% |
| 2015 Q3 | -11.87 Thousand CAD | 18.48% |
| 2015 Q1 | -8621.00 CAD | -9.28% |
| 2014 Q4 | -7889.00 CAD | 55.77% |
| 2014 Q1 | -9583.00 CAD | -216.58% |
| 2014 FY | - CAD | -164.3% |
| 2014 Q3 | -17.83 Thousand CAD | 78.99% |
| 2014 Q2 | -84.91 Thousand CAD | -786.12% |
| 2013 FY | - CAD | -251.53% |
| 2013 Q4 | -3027.00 CAD | -442.03% |
| 2013 Q3 | 885.00 CAD | 104.76% |
| 2013 Q2 | -18.58 Thousand CAD | -1789.02% |
| 2013 Q1 | -984.00 CAD | 89.8% |
| 2012 Q1 | -32.98 Thousand CAD | -94.83% |
| 2012 Q4 | -9645.00 CAD | 14.32% |
| 2012 Q2 | -21.51 Thousand CAD | 34.76% |
| 2012 FY | - CAD | 137.62% |
| 2012 Q3 | -11.25 Thousand CAD | 47.69% |
| 2011 Q2 | -36.89 Thousand CAD | -386.65% |
| 2011 Q3 | -5105.00 CAD | 86.16% |
| 2011 Q4 | -16.92 Thousand CAD | -231.62% |
| 2011 FY | - CAD | 15.3% |
| 2011 Q1 | -7582.00 CAD | 38.6% |
| 2010 Q2 | -14.15 Thousand CAD | -100.82% |
| 2010 Q1 | -7050.00 CAD | 86.91% |
| 2010 FY | - CAD | -1074.96% |
| 2010 Q4 | -12.34 Thousand CAD | -13.39% |
| 2010 Q3 | -10.89 Thousand CAD | 23.08% |
| 2009 Q3 | -4886.00 CAD | -142.0% |
| 2009 FY | - CAD | -101.39% |
| 2009 Q1 | -1225.00 CAD | 40.1% |
| 2009 Q4 | -53.86 Thousand CAD | -1002.37% |
| 2009 Q2 | -2019.00 CAD | -64.82% |
| 2008 Q3 | -4516.00 CAD | 0.0% |
| 2008 Q4 | -2045.00 CAD | 54.72% |
| 2008 FY | - CAD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Algernon Pharmaceuticals Inc. | -4.98 Million CAD | 39.28% |
| Asep Medical Holdings Inc | -8.13 Million CAD | 62.823% |
| BetterLife Pharma Inc. | -3.19 Million CAD | 5.224% |
| BioVaxys Technology Corp. | -7.68 Million CAD | 60.653% |
| ChitogenX Inc. | -2.69 Million CAD | -12.277% |
| Defence Therapeutics Inc. | -12.67 Million CAD | 76.138% |
| Entheon Biomedical Corp. | 13.99 Thousand CAD | 21716.072% |
| Gemina Laboratories Ltd. | -5.17 Million CAD | 41.56% |
| Glow Lifetech Corp. | -1.26 Million CAD | -139.481% |
| Lexston Life Sciences Corp. | -648.32 Thousand CAD | -366.547% |
| Pharmala Biotech Holdings Inc. | -710.18 Thousand CAD | -325.908% |
| Doseology Sciences Inc. | -319.47 Thousand CAD | -846.775% |
| MYND Life Sciences Inc. | -1.82 Million CAD | -65.721% |
| Nova Mentis Life Science Corp. | -1.2 Million CAD | -151.579% |
| PharmaTher Holdings Ltd. | -3.04 Million CAD | 0.612% |
| PreveCeutical Medical Inc. | -955.08 Thousand CAD | -216.697% |
| Telescope Innovations Corp. | -5.49 Million CAD | 44.909% |